Phe(576) plays an important role in the secondary structure and intracellular signaling of the human luteinizing hormone chorionic gonadotropin receptor

被引:8
|
作者
Yano, K
Kohn, LD
Saji, M
Okuno, A
Cutler, GB
机构
[1] NIDDKD, CELL REGULAT SECT, METAB DIS BRANCH, NIH, BETHESDA, MD 20892 USA
[2] NICHHD, DEV ENDOCRINOL BRANCH, NIH, BETHESDA, MD 20892 USA
[3] JOHNS HOPKINS UNIV, DEPT SURG, BALTIMORE, MD 21205 USA
来源
关键词
D O I
10.1210/jc.82.8.2586
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent studies have identified multiple activating mutations in the sixth transmembrane domain of LH/chorionic gonadotropin receptor (LH-CGR) in patients with male-limited precocious puberty. Computer analysis suggested that these mutations had an effect on the secondary structure of the third cytoplasmic loop and sixth transmembrane domain, and that Phe(576) was a critical conformational bridging residue between these regions that might be important for receptor activity. We made four amino acid substitutions of the Phe(576) (F576I, F576G, F576Y, F576E) in the LH/CG receptor to analyze its functional role. Computer analysis of secondary structure predicted that the F576E mutant changed the secondary structure to a totally helical conformation in the region of the third intracellular and sixth transmembrane domain. In contrast, the F576G, F576I, and F576Y mutants were predicted to change the helical conformation in the legion to an extended conformation. In expression studies, mutations of Phe(576) produced functional changes in cAMP and inositol phosphate (IP) signaling, and human CG (hCG) binding. Mutations predicted to cause an extended conformation exhibited two functional patterns: first, constitutively activating in cAMP signaling without changes in IP signaling or hCG binding (F576I and F576G), and second, constitutively activating in cAMP signaling with decreased hCG-induced cAMP and IP signaling and with both higher affinity and lower capacity of hCG binding (F576Y). The mutation predicted to cause a totally helical conformation resulted in no cAMP response and a minimal IP response to hCG stimulation, with negligible hCG binding (F576E). These data suggest that the common change induced by the F576I, F576G, and F576Y mutations to an extended conformation on the third cytoplasmic loop and sixth transmembrane domain of the LH/CGR results in increased Gs coupling and activation of adenylyl cyclase, The F576Y mutation appears to have an additional effect, beyond a modification in receptor conformation, that lends to higher affinity and lower capacity of hCG binding, as well as altered Gq coupling and phospholipase C activation The F576E mutation has a distinct and different impact on receptor conformation, which leads to negligible hCG binding and minimal function; however, the F576E mutation may provide a clue to understanding the receptor mutations that result in loss of function and pseudohermaphroditism. We conclude that Phe(576) plays an important role in the human LH/CGR with respect to receptor conformation, Gs coupling, and cAMP signaling consistent with predictions from mutations associated with male-limited precocious puberty.
引用
收藏
页码:2586 / 2591
页数:6
相关论文
共 50 条
  • [21] INCREASED EXPRESSION OF LUTEINIZING-HORMONE HUMAN CHORIONIC-GONADOTROPIN RECEPTOR GENE IN HUMAN ENDOMETRIAL CARCINOMAS
    LIN, J
    LEI, ZM
    LOJUN, S
    RAO, CV
    SATYASWAROOP, PG
    DAY, TG
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (05): : 1483 - 1491
  • [22] The role of luteinizing hormone/human chorionic gonadotropin receptor-specific mRNA binding protein in regulating receptor expression in human ovarian granulosa cells
    Nair, Anil K.
    Peegel, Helle
    Menon, K. M. J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06): : 2239 - 2243
  • [23] Absence of exon 10 of the human luteinizing hormone (LH) receptor impairs LH, but not human chorionic gonadotropin action
    Müller, T
    Gromoll, J
    Simoni, M
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05): : 2242 - 2249
  • [24] Pregnancy-associated Cushing's syndrome secondary to a luteinizing hormone/human chorionic gonadotropin receptor-positive adrenal carcinoma
    Wy, LA
    Carlson, HE
    Kane, P
    Li, X
    Lei, ZM
    Rao, CV
    GYNECOLOGICAL ENDOCRINOLOGY, 2002, 16 (05) : 413 - 417
  • [25] INHIBITION OF TESTICULAR LUTEINIZING-HORMONE RECEPTOR LEVEL BY TREATMENT WITH A POTENT LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST OR HUMAN CHORIONIC-GONADOTROPIN
    AUCLAIR, C
    KELLY, PA
    LABRIE, F
    COY, DH
    SCHALLY, AV
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1977, 76 (03) : 855 - 862
  • [26] EXPRESSION OF FUNCTIONAL HUMAN CHORIONIC-GONADOTROPIN HUMAN LUTEINIZING-HORMONE RECEPTOR GENE IN HUMAN UTERINE ARTERIES
    TOTH, P
    LI, X
    RAO, CV
    LINCOLN, SR
    SANFILIPPO, JS
    SPINNATO, JA
    YUSSMAN, MA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (01): : 307 - 315
  • [27] STIMULATORY EFFECT OF LUTEINIZING-HORMONE AND HUMAN CHORIONIC-GONADOTROPIN ON TESTICULAR PROLACTIN RECEPTOR LEVELS
    KELLY, PA
    SEGUIN, C
    CUSAN, L
    LABRIE, F
    BIOLOGY OF REPRODUCTION, 1980, 23 (05) : 924 - 928
  • [28] Seminal vesicles are novel sites of luteinizing hormone human chorionic gonadotropin-receptor gene expression
    Tao, YX
    Lei, ZM
    Rao, CV
    JOURNAL OF ANDROLOGY, 1998, 19 (03): : 343 - 347
  • [29] The urinary bladder of a woman is a novel site of luteinizing hormone human chorionic gonadotropin receptor gene expression
    Tao, YX
    Heit, M
    Lei, ZM
    Rao, CV
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (04) : 1026 - 1031
  • [30] 3' untranslated region-mediated regulation of luteinizing hormone human chorionic gonadotropin receptor expression
    Lu, DL
    Menon, KMJ
    BIOCHEMISTRY, 1996, 35 (38) : 12347 - 12353